1/15
Vocabulary review flashcards covering pathophysiology, diagnostic tests, and pharmacological therapies for Primary Biliary Cholangitis from the NASP 2025 CSP Exam Prep Course.
Primary Biliary Cholangitis (PBC)
An autoimmune disorder characterized by the gradual destruction of intrahepatic bile ducts, resulting in periportal inflammation, cholestasis, and potential progression to cirrhosis and portal hypertension.
Sicca Syndrome
An autoimmune condition presenting with dry eyes and dry mouth that frequently co-occurs with primary biliary cholangitis and adversely affects patient health-related quality of life.
Alkaline Phosphatase (ALP)
A key diagnostic and prognostic biomarker in PBC whose consistent elevation correlates with cholestasis, bile duct destruction, and increased risk of disease progression.
Anti-Mitochondrial Antibodies (AMAs)
Highly reliable diagnostic autoimmune antibodies that almost never occur in individuals without primary biliary cholangitis, even in the presence of other liver disorders.
Ursodeoxycholic Acid (UDCA)
The standard-of-care, first-line FDA-approved hydrophilic bile salt for PBC; it stabilizes hepatocyte membranes against toxic bile salts, inhibits apoptosis and fibrosis, and delays histological progression to cirrhosis when dosed at 13–15mg/kg daily.
UDCA Biochemical Response Goal
A therapeutic target evaluated after 6 to 12 months of ursodeoxycholic acid therapy defined as an ALP level <1.67×ULN along with normal bilirubin.
Obeticholic Acid (OCA)
A farnesoid X receptor agonist approved for patients who do not tolerate or fail to respond to UDCA; reduces ALP, GGT, and transaminases through antifibrotic and choleretic properties but does not improve survival or disease-related symptoms.
Livdelzi (seladelpar)
A peroxisome proliferator-activated receptor (PPAR)-delta agonist indicated as monotherapy or with UDCA for PBC, administered at an oral dosage of 10mg once daily with or without food.
Iqirvo (elafibranor)
A dual peroxisome proliferator-activated receptor (PPAR) agonist and weak CYP3A4 inducer indicated for PBC at a dosage of 80mg orally once daily with or without food.
Livdelzi Contraindicated/Avoided Concomitant Medications
Concomitant use is specifically avoided with Organic Anion Transporter 3 (OAT3) inhibitors and strong CYP2C9 inhibitors.
Elafibranor Contraceptive Advisory
Because elafibranor is a weak CYP3A4 inducer that reduces the reliability of hormonal contraceptives, females of reproductive potential must switch to effective non-hormonal contraception or add a barrier method during therapy and for at least 3 weeks after the final dose.
Bile Acid Sequestrant Dosing Separation
UDCA must be separated by ≥1hr before or ≥4hrs after bile-acid sequestrants; Livdelzi and Iqirvo must be administered at least 4hours before or 4hours after a bile acid sequestrant.
FibroScan
A specialized imaging test utilized in primary biliary cholangitis to noninvasively detect and quantify scarring (fibrosis) of the liver.
Magnetic Resonance Elastography (MRE)
An advanced imaging technique used to evaluate liver stiffness and detect liver hardening that may signal the development of cirrhosis.
Magnetic Resonance Cholangiopancreatography (MRCP)
A specialized magnetic resonance imaging examination designed to produce detailed structural images of the internal organs and biliary duct system.
Ascites Management in PBC
Interventions for abdominal fluid accumulation secondary to portal hypertension; mild cases require dietary sodium restriction, whereas severe cases require diuretics or paracentesis.